Boston Scientific BSX recently announced the completion of the first commercial cases in the United States with its FDA-approved Farapulse Pulsed Field Ablation (PFA) system. In January 2024, the ...

The approval comes on the heels of competition eating into Boston Scientific’s shares in the pulsed field ablation market.

Boston Scientific updated its forecast for pulsed field ablation (PFA) adoption, predicting that more than 60% of atrial fibrillation (AFib) procedures globally will use the technology by 2026. The ...

Boston Scientific announced today that its Farapulse pulsed-field ablation (PFA) system has received expanded CE mark ...

Boston Scientific has received US Food and Drug Administration (FDA) approval for the Farapulse Pulsed Field Ablation (PFA) system for the isolation of pulmonary veins in the treatment of ...

Boston Scientific has received Food and Drug Administration approval for a new pulsed field ablation catheter that is indicated for use as an adjunctive device in a type of ablation that is performed ...

Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific BSX ...

Boston Scientific, Inc. BSX recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of ...